Targeting the untargetable cancer—rezatapopt, an oral p53 reactivator
Medical Xpress
March 2, 2026
Memorial Sloan Kettering Cancer Center investigators and collaborators have tested rezatapopt, an oral p53 reactivator designed for tumors with TP53 Y220C, and observed antitumor activity across multiple solid tumor types in a phase 1 trial. Rezatapopt specifically binds Y220C-mutated p53, stabilizes p53 in a wild-type conformation, and restores p53 function.
Verticals
healthmedical
Originally published on Medical Xpress on 3/2/2026